Lumizyme
(Alglucosidase alfa)ApprovedProtein / enzyme
Alglucosidase alfa is used to treat Pompe disease, a rare genetic disorder where the body cannot break down a sugar called glycogen, causing it to build up in muscles and weaken them over time.[2] Lumizyme is currently approved and in use across 5 indications[4].[1]
Lumizyme is one of 60 small molecule programs targeting Disorder of Glycogen Metabolism. It is currently in Approved.
5
Indications
21
Total Trials
3
Active Trials
59
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
364 competitors in Growth
#DrugCompanyPhaseTrials
1Lumizyme
GGenzyme, a Sanofi Company
Approved
Genotropin
EMD SeronoPreclinical
Lovenox
SanofiPreclinical
Aricept
EisaiPreclinical
Zolymbus
AbbViePreclinical
Lenvima
EisaiPreclinical
Somavaratan
Novo NordiskPreclinical
Herceptin
OOrganon and Co
Preclinical
Glucophage
EMD SeronoPreclinical
EGRIFTA WR
TTheratechnologies
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pompe Disease13 trials
Show 10 more trials
Glycogen Storage Disease Type II2 trials
3 more indications
Regulatory
FDA Approval Timeline[5]
May 24, 2010
LUMIZYME
BLA BLA125291
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lumizyme drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Alglucosidase alfa. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[3]
- Highest Phase
- Approved[1]
- Company
- GGenzyme, a Sanofi Company